Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech A/S, operating also under the name NovVac A/S, aims to develop advanced software for creating new immune therapies and vaccines. The company has a share capital of DKK 54,110,546, divided into equal shares, and has authorized its board to issue warrants and increase share capital until April 2029 to incentivize its directors, executives, and key employees. These shares and warrants are non-negotiable and come with no special redemption obligations for shareholders.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
